Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Achondroplasia
- Main trialPhase 2/3
- “This is a multicenter, multinational, randomized, active-controlled, operationally seamless Phase 2/3 study of BMN 333 in treatment-naïve pediatric participants with achondroplasia (ACH). The study consists of a Phase 2 part and a Phase 3 part.”In the company’s words, NCT07441876 on ClinicalTrials.gov
Other drugs for Achondroplasia
- NavepegritideAscendis Pharma A/S · Phase 3
- VosoritideBioMarin Pharmaceutical · Phase 3
- LonapegsomatropinAscendis Pharma Endocrinology Division A/S · Phase 3
- KK8398Kyowa Kirin Co., Ltd. · Phase 3
- ABSK061Abbisko Therapeutics Co, Ltd · Phase 1/2
- DabogratinibTyra Biosciences, Inc · Phase 2
Coming up1
- Jun 2029Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Jun 2029 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026